Ioxilan

CHEMBL1201075 Phase 4 Disetujui Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
791.1 g/mol
LogP
-2.4
Phase
4

This non-ionic, low-osmolality iodinated contrast medium is used for urography, angiography, and CT imaging. It provides good visualization of blood vessels and body structures with a favorable tolerability profile due to its low osmolality. As with all iodinated contrast agents, patients should be monitored for allergic reactions and kidney function should be assessed.

Berat Molekul

791,1000 g/mol

LogP

-2,40

TPSA

180,00 Ų

Lipinski RO5

Gagal

Mekanisme Kerja

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mekanisme

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Struktur 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCCO)c(I)c(C(=O)NCC(O)CO)c1I

InChI

InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)

Molecular Formula

C18H24I3N3O8

HBD / HBA

7 / 8

Ikatan yang Dapat Dirotasi

11

Atom Berat

32

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This non-ionic, low-osmolality iodinated contrast medium is used for urography, angiography, and CT imaging. It provides good visualization of blood vessels and body structures with a favorable tolerability profile due to its low osmolality. As with all iodinated contrast agents, patients should be monitored for allergic reactions and kidney function should be assessed.

Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.

Yes, Ioxilan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201075. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3743. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.